Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 67

1.

A Randomized Multicenter Phase II Study of Docosahexaenoic Acid in Patients with a History of Breast Cancer, Premalignant Lesions, or Benign Breast Disease.

Gucalp A, Zhou XK, Cook ED, Garber JE, Crew KD, Nangia JR, Bhardwaj P, Giri DD, Elemento O, Verma A, Wang H, Lee JJ, Vornik LA, Mays C, Weber D, Sepeda V, O'Kane H, Krasne M, Williams S, Morris PG, Heckman-Stoddard BM, Dunn BK, Hudis CA, Brown PH, Dannenberg AJ.

Cancer Prev Res (Phila). 2018 Apr;11(4):203-214. doi: 10.1158/1940-6207.CAPR-17-0354. Epub 2018 Feb 16.

2.

Adjuvant therapy in patients with ductal carcinoma in situ of the breast: The Pandora's box.

Lazzeroni M, Dunn BK, Pruneri G, Jereczek-Fossa BA, Orecchia R, Bonanni B, DeCensi A.

Cancer Treat Rev. 2017 Apr;55:1-9. doi: 10.1016/j.ctrv.2017.01.010. Epub 2017 Feb 11. Review.

PMID:
28262606
3.

Cancer Prevention: Lessons Learned and Future Directions.

Dunn BK, Kramer BS.

Trends Cancer. 2016 Dec;2(12):713-722. doi: 10.1016/j.trecan.2016.11.003. Review.

4.

Raloxifene hydrochloride for breast cancer risk reduction in postmenopausal women.

Provinciali N, Suen C, Dunn BK, DeCensi A.

Expert Rev Clin Pharmacol. 2016 Oct;9(10):1263-1272. doi: 10.1080/17512433.2016.1231575. Epub 2016 Sep 12.

PMID:
27583816
5.

Immunologic approaches to cancer prevention-current status, challenges, and future perspectives.

Wojtowicz ME, Dunn BK, Umar A.

Semin Oncol. 2016 Feb;43(1):161-172. doi: 10.1053/j.seminoncol.2015.11.001. Epub 2015 Nov 14. Review.

PMID:
26970135
6.

Repurposing old drugs to chemoprevention: the case of metformin.

Heckman-Stoddard BM, Gandini S, Puntoni M, Dunn BK, DeCensi A, Szabo E.

Semin Oncol. 2016 Feb;43(1):123-133. doi: 10.1053/j.seminoncol.2015.09.009. Epub 2015 Sep 8. Review.

7.

The promise of omics-based approaches to cancer prevention.

Meerzaman D, Dunn BK, Lee M, Chen Q, Yan C, Ross S.

Semin Oncol. 2016 Feb;43(1):36-48. doi: 10.1053/j.seminoncol.2015.09.004. Epub 2015 Sep 8. Review.

PMID:
26970123
8.

Introduction: Cancer chemoprevention and its context.

Dunn BK, Umar A, Richmond E.

Semin Oncol. 2016 Feb;43(1):19-21. doi: 10.1053/j.seminoncol.2015.11.002. Epub 2015 Nov 10. No abstract available.

9.

Predictive Value Tools as an Aid in Chemopreventive Agent Development.

Dunn BK, Steele VE, Fagerstrom RM, Topp CF, Ransohoff D, Cunningham C, Lubet R, Ford LG, Kramer BS.

J Natl Cancer Inst. 2015 Sep 28;107(12):djv259. doi: 10.1093/jnci/djv259. Print 2015 Dec.

10.

Metformin: risk-benefit profile with a focus on cancer.

Provinciali N, Lazzeroni M, Cazzaniga M, Gorlero F, Dunn BK, DeCensi A.

Expert Opin Drug Saf. 2015 Oct;14(10):1573-85. doi: 10.1517/14740338.2015.1084289. Epub 2015 Sep 11. Review.

PMID:
26359221
11.

Legislation in the genomic era: the Affordable Care Act and genetic testing for cancer risk assessment.

Walcott FL, Dunn BK.

Genet Med. 2015 Dec;17(12):962-4. doi: 10.1038/gim.2015.18. Epub 2015 Mar 5. No abstract available.

PMID:
25741860
12.

JNCI and cancer prevention.

Dunn BK, Ghosh S, Kramer BS.

J Natl Cancer Inst. 2015 Feb 24;107(3). pii: djv021. doi: 10.1093/jnci/djv021. Print 2015 Mar.

13.

A randomized phase II presurgical trial of transdermal 4-hydroxytamoxifen gel versus oral tamoxifen in women with ductal carcinoma in situ of the breast.

Lee O, Page K, Ivancic D, Helenowski I, Parini V, Sullivan ME, Margenthaler JA, Chatterton RT Jr, Jovanovic B, Dunn BK, Heckman-Stoddard BM, Foster K, Muzzio M, Shklovskaya J, Skripkauskas S, Kulesza P, Green D, Hansen NM, Bethke KP, Jeruss JS, Bergan R, Khan SA.

Clin Cancer Res. 2014 Jul 15;20(14):3672-82. doi: 10.1158/1078-0432.CCR-13-3045.

14.

Metformin and cancer risk and mortality: a systematic review and meta-analysis taking into account biases and confounders.

Gandini S, Puntoni M, Heckman-Stoddard BM, Dunn BK, Ford L, DeCensi A, Szabo E.

Cancer Prev Res (Phila). 2014 Sep;7(9):867-85. doi: 10.1158/1940-6207.CAPR-13-0424. Epub 2014 Jul 1. Review.

15.

Genome-wide transcriptional sequencing identifies novel mutations in metabolic genes in human hepatocellular carcinoma.

Meerzaman DM, Yan C, Chen QR, Edmonson MN, Schaefer CF, Clifford RJ, Dunn BK, Dong L, Finney RP, Cultraro CM, Hu Y, Yang Z, Nguyen CV, Kelley JM, Cai S, Zhang H, Zhang J, Wilson R, Messmer L, Chung YH, Kim JA, Park NH, Lyu MS, Song IH, Komatsoulis G, Buetow KH.

Cancer Genomics Proteomics. 2014 Jan-Feb;11(1):1-12.

PMID:
24633315
16.

The Affordable Care Act and genetic testing for inheritable cancer syndromes: impact on high-risk underserved minorities.

Walcott FL, Dunn BK, DeShields M, Baquet C.

J Health Care Poor Underserved. 2014 Feb;25(1 Suppl):46-62. doi: 10.1353/hpu.2014.0070.

PMID:
24583487
17.

The word "cancer": how language can corrupt thought.

Dunn BK, Srivastava S, Kramer BS.

BMJ. 2013 Sep 10;347:f5328. doi: 10.1136/bmj.f5328. No abstract available.

PMID:
24022035
18.

Selenium and prostate cancer prevention: insights from the selenium and vitamin E cancer prevention trial (SELECT).

Nicastro HL, Dunn BK.

Nutrients. 2013 Apr 3;5(4):1122-48. doi: 10.3390/nu5041122. Review.

19.

Exemestane: one part of the chemopreventive spectrum for ER-positive breast cancer.

Dunn BK, Cazzaniga M, DeCensi A.

Breast. 2013 Jun;22(3):225-37. doi: 10.1016/j.breast.2013.02.015. Epub 2013 Mar 25. Review.

PMID:
23535509
20.

Future directions in cancer prevention.

Umar A, Dunn BK, Greenwald P.

Nat Rev Cancer. 2012 Dec;12(12):835-48. doi: 10.1038/nrc3397. Epub 2012 Nov 15. Review.

PMID:
23151603
21.

Oral low dose and topical tamoxifen for breast cancer prevention: modern approaches for an old drug.

Lazzeroni M, Serrano D, Dunn BK, Heckman-Stoddard BM, Lee O, Khan S, Decensi A.

Breast Cancer Res. 2012 Oct 29;14(5):214. doi: 10.1186/bcr3233. Review.

22.

Exemestane for breast cancer prevention: a critical shift?

Decensi A, Dunn BK, Puntoni M, Gennari A, Ford LG.

Cancer Discov. 2012 Jan;2(1):25-40. doi: 10.1158/2159-8290.CD-11-0248. Review.

23.

Biomarkers as molecular targets of drug interventions.

Smith JJ, Dunn BK.

Semin Oncol Nurs. 2012 May;28(2):109-15. doi: 10.1016/j.soncn.2012.03.004. Review.

PMID:
22542318
24.

Biomarkers as surrogate endpoints in cancer trials.

Dunn BK, Akpa E.

Semin Oncol Nurs. 2012 May;28(2):99-108. doi: 10.1016/j.soncn.2012.03.006. Review.

PMID:
22542317
25.

Introduction.

Smith JJ, Dunn BK.

Semin Oncol Nurs. 2012 May;28(2):85-6. doi: 10.1016/j.soncn.2012.03.001. No abstract available.

PMID:
22542314
26.

Biomarkers for early detection and as surrogate endpoints in cancer prevention trials: issues and opportunities.

Dunn BK, Jegalian K, Greenwald P.

Recent Results Cancer Res. 2011;188:21-47. doi: 10.1007/978-3-642-10858-7_3. Review.

PMID:
21253787
27.

Novel pathway analysis of genomic polymorphism-cancer risk interaction in the Breast Cancer Prevention Trial.

Dunn BK, Greene MH, Kelley JM, Costantino JP, Clifford RJ, Hu Y, Tang G, Kazerouni N, Rosenberg PS, Meerzaman DM, Buetow KH.

Int J Mol Epidemiol Genet. 2010;1(4):332-49. Epub 2010 Sep 5.

28.

Pathologic findings following false-positive screening tests for ovarian cancer in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial.

Nyante SJ, Black A, Kreimer AR, Duggan MA, Carreon JD, Kessel B, Buys SS, Ragard LR, Johnson KA, Dunn BK, Lamerato L, Commins JM, Berg CD, Sherman ME.

Gynecol Oncol. 2011 Mar;120(3):474-9. doi: 10.1016/j.ygyno.2010.11.015. Epub 2010 Dec 7.

29.

A nutrient approach to prostate cancer prevention: The Selenium and Vitamin E Cancer Prevention Trial (SELECT).

Dunn BK, Richmond ES, Minasian LM, Ryan AM, Ford LG.

Nutr Cancer. 2010;62(7):896-918. doi: 10.1080/01635581.2010.509833. Review.

PMID:
20924966
30.

The application of genetics and genomics to cancer prevention.

Calzone K, Wattendorf D, Dunn BK.

Semin Oncol. 2010 Aug;37(4):407-18. doi: 10.1053/j.seminoncol.2010.05.005. Review.

PMID:
20816510
31.

Epidemiology of health disparities in relation to the biology of estrogen receptor-negative breast cancer.

Agurs-Collins T, Dunn BK, Browne D, Johnson KA, Lubet R.

Semin Oncol. 2010 Aug;37(4):384-401. doi: 10.1053/j.seminoncol.2010.05.002. Review.

PMID:
20816508
32.

Breast cancer prevention trials: large and small trials.

Arun B, Dunn BK, Ford LG, Ryan A.

Semin Oncol. 2010 Aug;37(4):367-83. doi: 10.1053/j.seminoncol.2010.05.004. Review.

PMID:
20816507
33.

Cancer Prevention II: Introduction.

Dunn BK, Greenwald P.

Semin Oncol. 2010 Aug;37(4):321-6. doi: 10.1053/j.seminoncol.2010.06.016. No abstract available.

PMID:
20816502
34.

Molecular markers for early detection.

Dunn BK, Wagner PD, Anderson D, Greenwald P.

Semin Oncol. 2010 Jun;37(3):224-42. doi: 10.1053/j.seminoncol.2010.05.007. Review.

PMID:
20709207
35.

Cancer prevention I: introduction.

Dunn BK, Greenwald P.

Semin Oncol. 2010 Jun;37(3):190-201. doi: 10.1053/j.seminoncol.2010.06.011. No abstract available.

PMID:
20709204
36.

Health disparities in breast cancer: biology meets socioeconomic status.

Dunn BK, Agurs-Collins T, Browne D, Lubet R, Johnson KA.

Breast Cancer Res Treat. 2010 Jun;121(2):281-92. doi: 10.1007/s10549-010-0827-x. Epub 2010 May 1. Review.

PMID:
20437200
37.

Influence of genetic background and tissue types on global DNA methylation patterns.

Yang HH, Hu N, Wang C, Ding T, Dunn BK, Goldstein AM, Taylor PR, Lee MP.

PLoS One. 2010 Feb 23;5(2):e9355. doi: 10.1371/journal.pone.0009355.

38.

Delineating genetic alterations for tumor progression in the MCF10A series of breast cancer cell lines.

Kadota M, Yang HH, Gomez B, Sato M, Clifford RJ, Meerzaman D, Dunn BK, Wakefield LM, Lee MP.

PLoS One. 2010 Feb 15;5(2):e9201. doi: 10.1371/journal.pone.0009201.

39.

Identification of novel gene amplifications in breast cancer and coexistence of gene amplification with an activating mutation of PIK3CA.

Kadota M, Sato M, Duncan B, Ooshima A, Yang HH, Diaz-Meyer N, Gere S, Kageyama S, Fukuoka J, Nagata T, Tsukada K, Dunn BK, Wakefield LM, Lee MP.

Cancer Res. 2009 Sep 15;69(18):7357-65. doi: 10.1158/0008-5472.CAN-09-0064. Epub 2009 Aug 25.

40.

Landmarks in the history of cancer epidemiology.

Greenwald P, Dunn BK.

Cancer Res. 2009 Mar 15;69(6):2151-62. doi: 10.1158/0008-5472.CAN-09-0416. Epub 2009 Mar 10. Erratum in: Cancer Res. 2009 Aug 15;69(16):6758.

41.

Phase 3 trials of aromatase inhibitors for breast cancer prevention: following in the path of the selective estrogen receptor modulators.

Dunn BK, Ryan A.

Ann N Y Acad Sci. 2009 Feb;1155:141-61. doi: 10.1111/j.1749-6632.2009.03688.x. Review.

PMID:
19250201
42.

Selenium and Vitamin E Cancer Prevention Trial: a nutrient approach to prostate cancer prevention.

Dunn BK, Ryan A, Ford LG.

Recent Results Cancer Res. 2009;181:183-93. Review.

PMID:
19213568
43.

Do we make optimal use of the potential of cancer prevention?

Greenwald P, Dunn BK.

Recent Results Cancer Res. 2009;181:3-17. Review.

PMID:
19213552
44.

Flaxseed supplementation (not dietary fat restriction) reduces prostate cancer proliferation rates in men presurgery.

Demark-Wahnefried W, Polascik TJ, George SL, Switzer BR, Madden JF, Ruffin MT 4th, Snyder DC, Owzar K, Hars V, Albala DM, Walther PJ, Robertson CN, Moul JW, Dunn BK, Brenner D, Minasian L, Stella P, Vollmer RT.

Cancer Epidemiol Biomarkers Prev. 2008 Dec;17(12):3577-87. doi: 10.1158/1055-9965.EPI-08-0008.

45.

Influence of genetic inheritance on global epigenetic states and cancer risk prediction with DNA methylation signature: challenges in technology and data analysis.

Lee MP, Dunn BK.

Nutr Rev. 2008 Aug;66 Suppl 1:S69-72. doi: 10.1111/j.1753-4887.2008.00072.x. No abstract available.

PMID:
18673495
46.

Introduction: diet, epigenetic events and cancer prevention.

Ross SA, Dwyer J, Umar A, Kagan J, Verma M, Van Bemmel DM, Dunn BK.

Nutr Rev. 2008 Aug;66 Suppl 1:S1-6. doi: 10.1111/j.1753-4887.2008.00055.x. No abstract available.

47.

Hormonal interventions to prevent hormonal cancers: breast and prostate cancers.

Dunn BK, Ford LG.

Eur J Cancer Prev. 2007 Jun;16(3):232-42. Review.

PMID:
17415094
48.

Prevention of hormone-related cancers: breast cancer.

Dunn BK, Wickerham DL, Ford LG.

J Clin Oncol. 2005 Jan 10;23(2):357-67. Review.

PMID:
15637398
49.

Early detection and risk assessment: proceedings and recommendations from the Workshop on Epigenetics in Cancer Prevention.

Verma M, Dunn BK, Ross S, Jain P, Wang W, Hayes R, Umar A.

Ann N Y Acad Sci. 2003 Mar;983:298-319.

PMID:
12724234
50.

Hypomethylation: one side of a larger picture.

Dunn BK.

Ann N Y Acad Sci. 2003 Mar;983:28-42. Review.

PMID:
12724210

Supplemental Content

Support Center